Loading
Life sciences · Journal article
Journal of Medicinal Chemistry · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Inducing homologous recombination repair (HRR) deficiency is an attractive strategy to expand the therapeutic scope of PARP inhibitors. Since BRD4 inhibition impairs HRR function and sensitizes cancer cells to PARP inhibition, we designed and synthesized a series of dual PARP/BRD4 inhibitors. Structure−activity relationship studies identified D6 as a potent dual inhibitor with low nanomolar inhibitory activities against PARP1 and BRD4. D6 exhibited potent antiproliferative activity in MDA-MB-231 and KP4 cells and induced cell cycle arrest, apoptosis, and inhibition of colony formation and metastasis-associated phenotypes. Mechanistically, D6 suppressed the BRD4-cJUN-CCL2 signaling axis, reducing macrophage recruitment and macrophage-mediated cancer cell invasion. In an MDA-MB-231 xenograft model, D6 inhibited tumor growth without obvious toxicity. These findings support D6 as a promising dual PARP/BRD4 inhibitor for cancer therapy.